Prototypical Stressors

Showing 726 to 750 of 874 Prototypical Stressors

ID	Prototypical Stressor Name	Associated Chemical(s): Name, CAS-RN, DTXSID	Associated AOPs

50	Rotenone	Rotenone, CAS-RN: 83-79-4, DTXSID6021248	2 AOPs 3: Inhibition of the mitochondrial complex I of nigro-striatal neurons leads to parkinsonian motor deficits 326: Increase in reactive oxygen species leading to growth inhibition via lipid peroxidation and decreased cell proliferation
66	Perchlorate	Perchlorate, CAS-RN: 14797-73-0, DTXSID6024252	2 AOPs 176: Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis 54: Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment
74	2,2',4,4'-Tetrahydroxybenzophenone	2,2',4,4'-Tetrahydroxybenzophenone, CAS-RN: 131-55-5, DTXSID5041306	2 AOPs 175: Thyroperoxidase inhibition leading to altered amphibian metamorphosis 152: Interference with thyroid serum binding protein transthyretin and subsequent adverse human neurodevelopmental toxicity
83	Emamectin benzoate	Emamectin benzoate, CAS-RN: 155569-91-8, DTXSID0034566	2 AOPs 161: Glutamate-gated chloride channel activation leading to neurotransmission inhibition associated mortality 160: Ionotropic gamma-aminobutyric acid receptor activation mediated neurotransmission inhibition leading to mortality
95	Amiodarone	Amiodarone, CAS-RN: 1951-25-3, DTXSID7022592	2 AOPs 555: Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure 560: Inhibition of Funny current (If) leading to Arrhythmias
118	Verapamil	(+/-)-Verapamil, CAS-RN: 52-53-9, DTXSID9041152	2 AOPs 261: L-type calcium channel blockade leading to heart failure via decrease in cardiac contractility 552: Inhibiton of L-Type Calcium Channels leading to heart failure via QT interval prolongation and Torsades de Pointes (TdP)
128	Benomyl	Benomyl, CAS-RN: 17804-35-2, DTXSID5023900	2 AOPs 106: Chemical binding to tubulin in oocytes leading to aneuploid offspring 561: Aromatase induction leading to estrogen receptor alpha activation via increased estradiol
133	Phenobarbital	Phenobarbital, CAS-RN: 50-06-6, DTXSID5021122	2 AOPs 162: Enhanced hepatic clearance of thyroid hormones leading to thyroid follicular cell adenomas and carcinomas in the rat and mouse 107: Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat
163	Tacrolimus (also FK506)	Tacrolimus, CAS-RN: 104987-11-3, DTXSID5046354	2 AOPs 154: Inhibition of Calcineurin Activity Leading to Impaired T-Cell Dependent Antibody Response 622: Calcineurin inhibitor induced nephrotoxicity leading to kidney failure
164	Tebufenozide	Tebufenozide, CAS-RN: 112410-23-8, DTXSID4034948	2 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade
173	Raloxifene	Raloxifene, CAS-RN: 84449-90-1, DTXSID3023550	2 AOPs 165: Antiestrogen activity leading to ovarian adenomas and granular cell tumors in the mouse 440: Hypothalamus estrogen receptors activity suppression leading to ovarian cancer via ovarian epithelial cell hyperplasia
175	PERFLUOROOCTANOIC ACID		2 AOPs 166: PPARalpha activation leading to pancreatic acinar tumors in the rat and mouse 37: PPARα activation leading to hepatocellular adenomas and carcinomas in rodents
178	Haloperidol	Haloperidol, CAS-RN: 52-86-8, DTXSID4034150	2 AOPs 170: Anti-dopaminergic activity leading to mammary adenomas and carcinomas in the SD rat 555: Inhibition, Ether-a-go-go (ERG) Voltage-Gated Potassium Channel leading to heart failure
203	Fluvoxamine	Fluvoxamine, CAS-RN: 54739-18-3, DTXSID2044002	2 AOPs 195: 5-hydroxytryptamine transporter (5-HTT) inhibition leading to population increase 203: 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline
208	Gemfibrozil	Gemfibrozil, CAS-RN: 25812-30-0, DTXSID0020652	2 AOPs 37: PPARα activation leading to hepatocellular adenomas and carcinomas in rodents 323: PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone
211	Fenofibrate	Fenofibrate, CAS-RN: 49562-28-9, DTXSID2029874	2 AOPs 37: PPARα activation leading to hepatocellular adenomas and carcinomas in rodents 323: PPARalpha Agonism Leading to Decreased Viable Offspring via Decreased 11-Ketotestosterone
238	Methoxyfenozide	Methoxyfenozide, CAS-RN: 161050-58-4, DTXSID3032628	2 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade
239	Halofenozide	Halofenozide, CAS-RN: 112226-61-6, DTXSID4032619	2 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade
241	20-hydroxyecdysone	20-Hydroxyecdysone, CAS-RN: 5289-74-7, DTXSID5040388	2 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade
242	Ponasterone A	Ponasterone A, CAS-RN: 13408-56-5, DTXSID0040595	2 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade
243	Chromafenozide	Chromafenozide, CAS-RN: 143807-66-3, DTXSID4057976	2 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade
248	RH-5849		2 AOPs 4: Ecdysone receptor agonism leading to mortality via suppression of Ftz-f1 342: Ecdysone receptor hyperactivation leading to mortality via mis-timed activation of nuclear receptor cascade
254	Silica nanoparticles		2 AOPs 209: Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP 481: AOPs of amorphous silica nanoparticles: ROS-mediated oxidative stress increased respiratory dysfunction and diseases.
255	Graphene oxide nanoparticles		2 AOPs 210: Activation of c-Jun N-terminal kinase (JNK) and Forkhead box O (FOXO) and reduction of WNT pathways leading to reproductive failure: Integrated multi-OMICS approach for AOP building 237: Substance interaction with lung resident cell membrane components leading to atherosclerosis via acute phase response
256	Polychlorinated dibenzodioxins		2 AOPs 152: Interference with thyroid serum binding protein transthyretin and subsequent adverse human neurodevelopmental toxicity 150: Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF